Anavex Life Sciences Corp (AVXL)

[Investor2014]

We don't have any baseline data against which to compare gut bacteria changes in A2-73 treated patients!

Slide 9 "1 stool collection event per patient, between week 77 and week 109 (variability caused by patient’s agreement and visit schedule)"

Slide 15, should have more accurately said "KEM® Identifies Differences in two Gut Microbiome Families - Ruminococcaceae and Porphyromonadaceae - Associated with Response to ANAVEX®2-73"

Slide 12, quoting Vogt et al. (2017) provides a generalised view of bacteria family abundance between healthy people and AD patients. So those patients that KEM found with higher abundance of Ruminococcaceae and Porphyromonadaceae is accordingly somewhat unusual in AD patients.

"ANAVEX®2-73 may have beneficial homeostatic effect on brain-gut-microbiota axis",

I prefer not to give this statement any credence at this time. There is nothing in the presentation that in anyway supports the idea that A2-73 has a positive direct or indirect effect on the gut. It could perhaps have, but I'd like to see data to support it. I can't see how Anavex could be hugging such data based on 1 poop per patient taken at one time between weeks 77 and 109.

What Anavex probably means is that there is something going on with the balance between certain bacteria families and the response to A2-73. It is just that their sentence seems more sexy.